<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191629</url>
  </required_header>
  <id_info>
    <org_study_id>VSH01</org_study_id>
    <nct_id>NCT04191629</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema</brief_title>
  <official_title>Phase 1 Clinical Study to Evaluate Safety and Tolerability of Magnetic Human Corneal Endothelial Cells in the Treatment of Corneal Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeria Sanchez-Huerta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emmecell</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, phase 1 study to evaluate the safety and tolerability of EO1404 in subjects
      with corneal edema secondary to pseudophakic bullous keratopathy or Fuch's endothelial
      dystrophy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2016</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of safety adverse events including worsening of corneal edema and increase in intraocular pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BVCA</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in corneal thickness</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Corneal Edema</condition>
  <condition>Fuchs Dystrophy</condition>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <condition>Pseudophakic Bullous Keratopathy</condition>
  <condition>Corneal Endothelial Dystrophy</condition>
  <condition>Corneal Transplant Failure</condition>
  <arm_group>
    <arm_group_label>50K to 200K cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50K to 200K cells with endothelial brushing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500K cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500K cells with endothelial brushing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EO1404</intervention_name>
    <arm_group_label>500K cells</arm_group_label>
    <arm_group_label>500K cells with endothelial brushing</arm_group_label>
    <arm_group_label>50K to 200K cells</arm_group_label>
    <arm_group_label>50K to 200K cells with endothelial brushing</arm_group_label>
    <other_name>Magnetic Human Corneal Endothelial Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endothelial brushing or Descemet stripping</intervention_name>
    <arm_group_label>500K cells with endothelial brushing</arm_group_label>
    <arm_group_label>50K to 200K cells with endothelial brushing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 21 years

          2. Pseudophakic with a posterior chamber intraocular lens.

          3. Symptomatic corneal edema associated with endothelial dysfunction which may be
             secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.

             a Symptoms including reduced vision and/or glare, and/or pain; subject may or may not
             have been on topical therapies such as 5% sodium chloride drops or prednisolone
             acetate 1% drops.

             b ETDRS-best corrected visual acuity worse than 20/63 on Snellen. c Central corneal
             thickness &lt; 2 mm by ultrasound pachymetry or OCT. d Subject must have progressed far
             enough in their clinical course to be considered a surgical candidate for
             full-thickness corneal transplantation or endothelial keratoplasty.

          4. Subject must understand and sign the informed consent. If the subject's vision is
             impaired to the point where he/she cannot read the informed consent document, the
             document will be read to the subject in their maternal language.

          5. Subject must be medically able and willing to undergo the protocol-required
             procedures.

        Exclusion Criteria:

        All ocular criteria apply to study eye unless otherwise noted.

          1. Other corneal disease, including active or prior herpetic ocular infection; active
             inflammation; corneal scarring from trauma, burns, or infection; or band keratopathy.

          2. Visual acuity in the fellow eye is worse than 20/200.

          3. Anterior chamber intraocular lens.

          4. Subject requires topical, intravenous or oral acyclovir and/or related products during
             study duration

          5. History of vitrectomy.

          6. History of refractive surgery.

          7. Macular disease that in the investigator and/or sponsor's opinion would limit the
             ability of the subject to demonstrate improvement in BCVA.

          8. Prior incisional eye surgery within 3 months prior to study treatment.

          9. Subject is receiving systemic steroids or other systemic immunosuppressive
             medications.

         10. Subject is currently participating in or has participated within the last 3 months in
             any other clinical trial of an investigational drug by ocular or systemic
             administration.

         11. History of uveitis or other ocular inflammatory disease.

         12. History of glaucoma, or peripheral anterior synechiae on gonioscopy.

         13. History of incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage
             implant).

         14. Female subject who is pregnant, nursing, or planning to become pregnant, or who is of
             childbearing potential and not using a reliable means of contraception during the
             study.

         15. Subject is immunodeficient, or tested positive for HIV.

         16. Subject is on chemotherapy.

         17. History of malignancy other than basal cell carcinoma, UNLESS the malignancy was
             treated successfully 5 years prior to inclusion in the study.

         18. History of ocular neoplasm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeria Sanchez-Huerta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociacion Para Evitar la Ceguera</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valeria Sanchez-Huerta, MD</last_name>
    <phone>+5210841400</phone>
    <phone_ext>1234</phone_ext>
    <email>valeriash@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociación Para Evitar la Ceguera en México, IAP, Hospital &quot;Dr. Luis Sánchez Bulnes&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanchez-Huerta Valeria, MD</last_name>
      <phone>10841400</phone>
      <phone_ext>1043</phone_ext>
    </contact>
    <investigator>
      <last_name>Sanchez-Huerta Valeria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>De Wit Carter Guillermo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hernandez-Chavarria Cesar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asociación para Evitar la Ceguera en México</investigator_affiliation>
    <investigator_full_name>Valeria Sanchez-Huerta</investigator_full_name>
    <investigator_title>Academic Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

